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ELISPOT assays. In order to remove these speciﬁc T cells from
the entire splenocyte population we took advantage of the PE
labeling on the LYL8 tetramer. Using anti-PE microbeads and
AUTOMACS separation, we have successfully depleted LYL8
tetramer positive T cells from both naı¨ve and immunized B6
spleens. Finally, we have been able to demonstrate that ex vivo
depletion of tetramer positive cells from naı¨ve B6 splenocytes prior
to adoptive transfer along with TCD-BM signiﬁcantly delayed the
onset of lethal GVHD post BMT (see table).
We have shown that speciﬁc depletion of antigen speciﬁc T cells
is a feasible and successful method for the elimination of GVHD in
this model.
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THERAPY FOR REFRACTORY ACUTE GRAFT VERSUS HOST DISEASE
(AGVHD) WITH BASILIXIMAB (BAMAB) - A SELECTIVE INTERLEUKIN-2
RECEPTOR (IL-2R) ANTAGONIST
Moreira, V.A., Bonﬁm, C.M., Bitencourt, M.A., Setubal, D.C., Loren-
zato, C., Ruiz, J., Zanis-Netto, J., de Medeiros, C.R., Pasquini, R. BMT
Center-Federal University of Parana, Curitiba, PR, Brazil
BaMab is a chimeric murin-human monoclonal antibody, which
binds to the alpha chain of IL-2R found predominantly on acti-
vated cytotoxic T-cells. The IL-2 activation of RAS pathway,
which activates lymphocyte proliferation, differentiation and de-
velopment of a-GVHD, is inhibited by this drug through a com-
petitive antagonism. We report our experience with BaMab as
therapy for refractory a-GVHD after BMT. Thirty-four patients
(pts) with severe refractory a-GVHD received BaMab from de-
cember 1998 to october, 2003. The latest 21 pts were treated as
part of a prospective protocol. Because of a 7 days (d) half-life,
BaMab schedule was 40mg weekly for 2-3 doses (adults) and 20
weekly for 2-3 doses (children). Age: 2-38 years (y) (M: 13 y); Sex
M/F: 21/13. Unrelated BMT: 25 pts; related BMT: 9 pts. Cell
source: Bone marrow: 30; Cord blood: 4. Diagnosis: AML(4 pts),
ALL(4 pts), MDS(4 pts), CML(9 pts), Fanconi anemia (9 pts), AAS
(3 pts), other (1pt). All pts had a-GVHD grade III-IV, manifesting
from day 6-248 after transplant (M: 24 d), when in use of cyclo-
sporin, and refractory to association with steroids (2-5mg/kg/d) for
7 to 70 d (M: 17 d). Sites of GVHD involvement: skin: 32 pts; GI:
25 pts; liver: 23pts. The ﬁrst administration day of BaMab occurred
between 21-256 d after BMT (M: 42 d). Median follow-up was
196 d (range: 35-1847 d). Overall response rate was 82% (CR: 11
pts, PR: 17 pts). Two pts (8 %) were not evaluated due to early
death. Skin GVHD CR (complete response): 27/32 pts (84,3 %),
PR (partial response) : 4/32 (12,5 %), NR (no response) :
1/32(3,2%); GI GVHD CR: 12/25 pts (48 %), PR: 8/25 pts(32 %),
NR : 4/25(16%), NA (not available): 1/25 (4%); liver GVHD CR
: 6/23 pt (26%), PR:7/23 (30,5%), NR : 8/23 pts (34,7%), NA:
2/23(8,8). Time to ﬁrst signs of response was 1-30 d (M: 7 d).
Duration of response varied from 5-1103 d (M: 38 d). There were
no infusion-related reactions. Estimated 5 y overall survival: 32%.
Eleven (11) pts are alive, 7 pts with CR, 3 PR and 1 pt SR (with
isolated skin GVHD). Main causes of death included: disseminated
CMV (4 pt), fungal infection (6 pts), sepsis (8 pts), haemorrhage
(2pts), and relapse (2 pts with ALL). GVHD relapses were seen on
14/34 pts (41%), but 7 pts (28%) were rescued with another
therapy (MMF, PUVA, steroids). BaMab administration is safe and
this drug is useful to treat refractory a-GVHD. Prospective studies
are necessary to evaluate its optimal treatment schedule and efﬁ-
cacy.
HISTOCOMPATIBILITY/ALTERNATIVE STEM
CELL SOURCES
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RESULTS OF THE CORD BLOOD TRANSPLANTATION STUDY (COBLT)
UNRELATED DONOR BANKING PROGRAM
Kurtzberg, J.1, Wagner, E.L.2, Fraser, J.K.3, Cairo, M.S.4, Jensen, L.2,
Cohen, G.5, Carter, S.L.5, Kernan, N.A.6 1. Duke University Medical
Center, Durham, NC; 2. National Heart, Lung, and Blood Institute,
Bethesda, MD; 3. University of California at Los Angeles, Los Angeles,
CA; 4. Georgetown University Medical Center, Washington, DC; 5.
The Emmes Corporation, Rockville, MD; 6. Memorial Sloan Kettering
Cancer Center, New York, NY
The COBLT banking program, initiated in 1996 with support
from the National Heart Lung and Blood Institute aimed to 1)
develop standard operating procedures (SOPs) for donor screen-
ing, recruitment and consenting and for collection, testing, pro-
cessing, cryopreservation, and thawing of unrelated donor umbil-
ical cord blood (UCB) and 2) build an ethnically diverse unrelated
cord blood bank to support a transplantation research protocol.
The program included multiple collection sites, 3 banks, a steering
committee and coordinating center which developed a web based
data collection system. Collections were initiated 12/97 and com-
pleted 7/2001. Screening data for 34,799 potential donors were
collected from 4/98 to 3/2001. Of these 10,599 (30%) were not
approached due to lack of informed consent or a COBLT exclu-
sion criterion. A total 20,710 mothers (60% of screened) were
approached and consented to participate in the program and UCB
was collected from 48 % of those screened and 81% of those
consented. 17,207 cord blood units (CBUs) of diverse ethnicity
were collected (40% Caucasian; 17% African-American; 11%
Asian; 20% Hispanic; 13% Mixed/Other). Of these, 11,096 (64%)
were cryopreserved and placed in quarantine. Of these, 49% passed
all eligibility criteria, were HLA-typed and entered into the
COBLT search registry. The reasons for exclusion after collection
were insufﬁcient volume or cell count (64%), a positive maternal
infectious disease test (8%) or a risk factor in the maternal history
(8%). The mean total viable nucleated, CD34, and CD3 cell
counts for the banked units were 9.2x10e8, 3.4x10e6 and 1.8x10e8,
respectively. The mean total CFU-GM count was 9.3x10e5. Rela-
tionships between ethnicity, route of delivery, birth weight, ma-
ternal age, gestational age, infant gender and UCB yields in banked
CBUs were examined. Higher cord blood volumes and total nu-
cleated cell count (TNC) were obtained from C-section compared
to vaginal deliveries. Units from African American donors con-
tained lower TNC counts per volume compared to other ethnici-
ties. UCB volume, TNC and CD34 cell content correlated with
birth weight. CD34 content decreased with increasing gesta-
tional age. The COBLT Program demonstrates that SOPs for
donor recruitment and consenting, collection, processing, cryo-
preservation, quality assurance, and data collection can be success-
fully developed and implemented in multiple banks coordinated by
a single coordinating center.
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EMBRYONIC STEM CELLS AS AN ALTERNATIVE DONOR MARROW
SOURCE: ENGRAFTMENT WITHOUT GVHD
Burt, R.K., Oyama, Y., Verda, L. Northwestern University, Chicago, IL
Hematopoietic stem cells (HSCs) have been considered unique
in their ability to reconstitute hematopoiesis following transplan-
tation into an immune compromised host. HSCs cannot be re-
newed ex vivo and must be individually collected from each donor
or patient resulting in inter-patient as well as intra-patient lot
Table. Clonal Deletion of LYL8-speciﬁc T Cells Prior to Adoptive
Transfer Signiﬁcantly Delays the Onset of GVHD
B6 Bone Marrow  N
Median
Survival
(Days)
P
Value
B6 T Cells 9 14 0.0055
LYL8- B6 T Cells 9 31
HSV8-B6 T Cells
(non-specific
control) 4 8 0.0003
*P values compare indicated group to LYL8- B6 T cells group.
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